Rybelsus
Semaglutide(oral)
Rybelsus is the first oral formulation of semaglutide, FDA-approved for type 2 diabetes management. While not officially indicated for weight loss, it’s sometimes prescribed off-label for patients seeking GLP-1 benefits without injections. Rybelsus reduces appetite, slows gastric emptying, and improves glycemic control, contributing to gradual weight reduction when combined with diet and exercise. Oral availability offers convenience and broader patient acceptance, although weight loss tends to be less robust than injectable GLP-1 formulations. Its off-label use for weight management should be supervised by healthcare professionals, considering dose limitations, insurance coverage, and careful monitoring for gastrointestinal side effects.
- Manufacturer: Novo Nordisk
- Primary Use: Type 2 Diabetes (weight loss off-label)
- Form: Oral
Common Side Effects
The most common side effects of Rybelsus may include:
- Nausea
- Abdominal Pain
- Diarrhea
- Decreased Appetite
This is not a complete list. Always consult with your healthcare provider about potential side effects.
Medical Disclaimer
The information provided for Rybelsus is for informational purposes only and is not a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment. Read our full disclaimer.